New drug combo targets tough pancreatic cancer gene

NCT ID NCT07656376

Not yet recruiting Disease control Sponsor: Jiangxi Kvvit Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new drug called DN022150 combined with standard chemotherapy (AG) as a first treatment for advanced pancreatic cancer that has a specific genetic change called KRAS G12D. About 465 adults aged 18-75 who have not had prior treatment for advanced disease will take part. The trial has two stages: first to find the best dose, then to compare the drug combo against chemo alone.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: DN022150 (a targeted drug) combined with AG chemotherapy (gemcitabine and nab-paclitaxel)
What this could lead to: If successful, this could provide a new first-line treatment option for people with a specific genetic type of advanced pancreatic cancer, potentially improving how long they live.
What could go wrong: This is an early-to-mid stage trial combining a new drug with standard chemo. The new drug may not add benefit, could cause added side effects, and results may not apply to all pancreatic cancer patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

exocrine pancreatic carcinoma malignant pancreatic neoplasm pancreatic adenocarcinoma pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PANCREATIC CANCER PANCREATIC CARCINOMA

More trials for these conditions

Other studies related to the condition(s) this trial covers.